ISRCTN90378590已完成不适用
Epidemiological studies on human papillomavirus (HPV)
ondon School of Hygiene & Tropical Medicine (UK)0 个研究点目标入组 330 人开始时间: 2009年1月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. Female subjects aged 10-25 years
- •2. Subjects who the investigator believes that they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol should be enrolled in the study
- •3. A female between, and including, 10 and 25 years of age at the time of the first vaccination
- •4. Written or oral, signed or thumb printed or witnessed informed consent obtained from the subject prior to enrolment for both the main GSK vaccine trial and for the epidemiological studies on HPV. For subjects below legal age of consent, written or oral, signed or thumb printed or witnessed informed consent obtained from the subject's parent or legally acceptable representative.
- •5. Free of obvious health problems as established by medical history, clinical examination and laboratory testing before entering into the study.
- •6. Subjects must have a negative urine pregnancy test at the screening visit and at Visit 1 (Day 0)
- •7. Subjects must be seronegative for human immunodeficiency virus (HIV) at the screening visit
- •8. Subjects must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. Subjects who reach menarche during the study and therefore are of childbearing potential must agree to follow the same precautions.
- •9. Subjects must have had no more than 6 sexual partners prior to enrolment
- •10. Subjects must be willing to undergo HIV voluntary counselling and testing and must be willing to be informed of their HIV status. Subjects below legal age of consent must also be willing to have their parent or legally acceptable representative informed of their HIV status.
排除标准
- •1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 12)
- •2. Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned administration during the study period
- •3. Administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. Enrolment will be deferred until the subject is outside of specified window.
- •4. Planned administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after any dose of study vaccine
- •5. Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period
- •6. Previous administration of components of the investigational vaccine
- •7. Cancer or autoimmune disease under treatment
- •8. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection based on laboratory testing performed during the screening visit
- •9. Hypersensitivity to latex
- •10. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control
- •11. Acute disease at the time of enrolment
- •12. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory testing performed at the screening visit
- •13. History of any neurologic disorders or seizures
- •14. Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
- •15. Pregnant or breastfeeding female
- •16. A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose
- •17. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device)
研究者
相似试验
已完成
不适用
HrHPV in the population research on cervical cancer.Cervical intraepithelial neoplasia and cervical cancer. Due to the low prevalence of invasive cervical cancer in the Netherlands, and the aim of cervical screening to prevent the occurrence of and death caused by to cervical cancer, we evaluate the prevalence of a surrogate marker for cervical cancer incidence, namely the immediate precursor lesion of cervical cancer cervical intra-epithelial neoplasia grade 3.NL-OMON28695- Department of Pathology, VU University Medical Center- Department of Pathology, Spaarne Ziekenhuis, Hoofddorp- Leiden Cytology and Pathology Laboratory, Leiden- Stichting PA Laboratorium Kennemerland, Haarlem44,102
尚未招募
Unknown
Presence of Human Papilloma virus and changes in the cervix in immunocompromised women in coastal KarnatakaCTRI/2023/03/050492university grant
已完成
不适用
Epidemiological analysis of human papillomavirus in western Kazakhstan in relation to HPV-attributable cervical pathology – social, clinical and genetic aspectsCervical cancerMalignant neoplasm of cervix uteriCancerISRCTN71514910Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan1,166
招募中
不适用
Prevalence and risk factors of Human papilloma virus and asymptomatic sexually transmitted infection among Thai transgender men.Healthy transgender menTransmen, transgender men, testosterone, HPV, Human Papillomavirus, Sexual transmitted infection, STITCTR20240409002Ratchadapiseksompoch funds357
招募中
不适用
Study on the Epidemiological Characteristics of Female HPV Vaccination in ChinaHuman Papillomavirus VaccinesAdverse EffectEpidemiologyChinaWomanNCT05932563Fujian Maternity and Child Health Hospital1,700